The purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in Chinese healthy adult subjects. 2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses. 3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses. 4. Determine the effect of doses of CK-3773274 on the pumping function of the heart. 5. Evaluate the effect CYP2D6 genetic polymorphisms on how the body metabolizes CK-3773274.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
28
CK-3773274- Tablets
Placebo- Tablets
Clinical Site
Beijing, Beijing Municipality, China
Subject incidence of Adverse Event (AE), Serious Adverse Event (SAE)
Time frame: SAD cohorts: Day-1 - Day10; MD cohort: Day-1 - Day 23
Reduced Left Ventricular Ejection Fraction (LVEF)
Time frame: SAD cohorts: Day-1 - Day10; MD cohort: Day-1 - Day 23
Cmax of CK-3773274 after single and multiple ascending doses
Time frame: SAD Cohorts: Day-1 - Day10; MD Cohort: Day-1 - Day 23
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.